Imaverol is relevant for managing Dermatophytosis, commonly known as ringworm, which involves controlling fungal colonization and affects cattle, horses, and dogs. The treatment is indicated for infections induced by pathogenic fungi, including Microsporum canis, Microsporum gypseum, and various Trichophyton species.

This medication is commonly used across conditions presenting with acute episodes resulting from active fungal invasion of the animal's skin and hair. The primary benefit may be part of symptomatic management, which may assist with addressing the condition and its progression. The indications are considered relevant for the therapeutic area of veterinary dermatology, specifically for fungal diseases like ringworm and skin infections caused by dermatophytes.

Imaverol is commonly used to help with symptoms that create noticeable physiological strain of fungal skin infections, including characteristic circular areas of hair loss (alopecia), underlying skin inflammation, and the formation of crusts and scaling. Managing the infection helps address the impact of these visible and uncomfortable epidermal surface abnormalities, contributing to improved day-to-day comfort during symptomatic periods. The treatment is often applied in clinical settings that involve acute or unstable symptom patterns, particularly to help control the highly contagious spread of dermatophytosis in animal groups.

“The strategic use of this medication supports maintaining a sense of stability within the group environment and may assist with reducing the risk of transmission.”

Quick Fact: Support for Dermatophyte-Induced Skin Lesions

Imaverol is relevant for easing symptoms that interfere with daily comfort, focusing on the active skin damage and scaling caused by common dermatophytes, including its role in managing potential subclinical foci—hidden fungal reservoirs.

Regulatory References

1. Veterinary Medicines Directorate (UK) Summary of Product Characteristics

Imaverol is strictly licensed and regulated as a veterinary medicinal product. Its official eligibility profile is defined by the authorized animal species and the absence of specific population-based restrictions in regulatory documents such as the Summary of Product Characteristics (SmPC).

Populations Allowed and Not Allowed

Conditional and Special Population Rules

Official regulatory information provides specific guidance for use in reproductive and young animal populations:

• Pregnancy and Lactation: The product may be given to pregnant animals and may be given to lactating animals (SmPC 4.7).
• Age-Related Use: Use is generally permitted in young animals, including calves, foals, and puppies, based on the absence of explicit age-based restrictions.
• Comorbid Conditions: No restrictions based on conditions like hepatic or renal impairment are documented in the official regulatory label.

Interactions with other medicines and products

Imaverol (enilconazole) is an antifungal agent primarily used in veterinary medicine as a topical treatment. The official regulatory profile for Imaverol, as defined by authoritative government agencies, indicates a lack of documented drug interactions.

Official Regulatory Statement

The most critical information in the official regulatory labeling concerning concomitant use is the explicit statement regarding a lack of known interactions. This statement applies across all typical interaction categories:

• Medicines: No specific medicinal products or therapeutic drug classes are listed as interacting substances. The regulatory documents do not designate any drug combinations as contraindicated due to interaction risk.
• Mechanisms: There are no documented pharmacokinetic or pharmacodynamic mechanisms—such as effects on CYP450 enzymes, drug transporters, or additive effects—that would necessitate warnings or precautions related to concomitant use.
• Other Substances: No interactions with food, alcohol, herbal supplements, or other topical products are documented in the official regulatory sections.

Practical Implications from Official Labeling

Because the regulatory documents state that none are known, the official label does not mandate any specific interaction-related constraints or requirements. This means no timing separation rules, dose adjustments, or population-specific considerations arising from documented interactions are included in the product's official prescribing information.

Imaverol targets and functions as a non-competitive inhibitor of the P450-dependent C14alpha-demethylase enzyme, which is critical for sterol synthesis in fungal cell membranes. By blocking this enzyme, Imaverol prevents the demethylation of lanosterol, leading to the accumulation of toxic C14-methylated sterols and a consequential depletion of ergosterol. Ergosterol depletion compromises the structural integrity and function of the fungal cell membrane, resulting in increased permeability. The subsequent loss of osmotic control triggers the uncontrolled influx of ions and macromolecules into the cell, which leads to organelle swelling and irreversible structural damage. This cellular damage is concentration-dependent, culminating in cell lysis and death as the ultimate physiological consequence of the mechanistic cascade.

How to Use Imaverol: Administration Guidelines

Imaverol (enilconazole 100 mg/mL Concentrate) is a veterinary medicine for topical use (cutaneous application) on cattle, horses, and dogs. The administration protocol requires dilution of the concentrated solution prior to use.

Preparation and Dosing

The concentrate must be diluted with warm water at a ratio of 1 part Imaverol to 50 parts water. This mixing creates the 0.2% (2 mg/mL) enilconazole working emulsion, which is the final preparation used for treating the animal. Any unused diluted solution must be disposed of after six weeks.

Application Procedure and Schedule

The treatment involves repeated application of the 0.2% emulsion:

• Frequency: Applications must be repeated every 3 days.
• Total Course: A total of 3 or 4 applications is required, depending on the species and lesion severity.

Before treatment, any large scabs or crusts should be removed using a hard brush soaked in the prepared emulsion. The animal, particularly for the first treatment, should be thoroughly washed or sprayed across the entire body to address subclinical lesions. For dogs, application must be rubbed against the hair growth or achieved via thorough dipping. Protective clothing, including gloves and safety glasses, must be worn during preparation and application, and the animal should be prevented from licking the product during treatment.

Imaverol: Overview of Studies

Evidence for Use in Dermatomycoses (Ringworm)

Research for Imaverol was studied in the context of fungal skin infections, or dermatomycoses, in the authorized target species: cattle, horses, and dogs. The evidence base includes both controlled clinical trials and field studies conducted during periods of increased symptom activity in target animal populations against specific Microsporum and Trichophyton species. The studies monitored outcomes related to physical discomfort by measuring the evolution of skin signs like scaling, crusts, and alopecia. Researchers also explored mycological status, monitoring the fungal culture negativity, which helps contextualize how infection is measured during the study period.

Evaluation of Long-Term Outcomes and Recurrence

Studies conducted during the medicine's evaluation sometimes included extended follow-up periods ranging from several weeks up to several months. This observation period was used in research exploring short-term symptom changes and to monitor the status of mycological monitoring over defined time intervals. Research describes the study designs used in research examining the frequency of recurrence after the treatment period was completed. The evidence provides insight into the short-term symptom patterns, which was observed in some studies to vary across animal populations. However, long-term effects are not fully established across all target species, and there is limited information for long-term outcomes regarding the exact frequency of relapse.

Research in Specific Animal Populations

The evidence landscape specifically includes studies focusing on certain subpopulations, such as young animals (calves), where the medicine was evaluated in conditions characterized by cycles of stability and flare-ups. Research also examined animals with both visible infections and those with subclinical foci (fungal carriage that is not yet obvious on the skin). Data for certain groups remain insufficient, especially when considering populations such as pregnant or severely debilitated animals, meaning that the full implications for these specific populations are not fully established in the research record.

Areas of Uncertainty and Research Gaps

The evidence quality varies across studies, and several research limitation frames apply to the existing body of work. For example, many published research reports are based on sample sizes that were modest, meaning the results apply only to the populations studied and may not generalize broadly. Furthermore, some studies involved a combination regimen with systemic antifungal agents, meaning the subgroup findings are uncertain regarding the independent action of the topical agent. Comparative evidence is lacking regarding some common alternative therapeutic approaches. While research provides context but not individual predictions, the follow-up durations were limited in many instances.

Key Studies & References

1. Summary of Product Characteristics (SPC) - Imaverol 100 mg/ml Concentrate for Cutaneous Emulsion (VMD, UK)

Common questions about Imaverol (FAQ)

Q: How quickly does Imaverol typically start working?

Clinical studies summarized in official reports indicate that the onset of clinical improvement has been noted in research populations after approximately 7 to 8 days of treatment. However, achieving a full mycological cure, meaning the complete elimination of the fungus, may take several weeks following the completion of the full treatment course.

Q: What does it mean if Imaverol doesn't seem to be working after a week?

The standard treatment schedule calls for three to four applications spaced three days apart. Official labeling acknowledges that in severe cases, the total treatment course may be extended. The regulatory label indicates that any modification or extension of the standard regimen is done under professional guidance.

Q: Is it normal to feel a mild burning sensation when using Imaverol?

The official safety information requires the person administering the product to perform immediate washing of the skin if the concentrate solution makes contact, due to the potential for irritation. Burning is not listed as a known adverse reaction associated with the diluted emulsion in the regulatory documents for the animal.

Q: Can I use alcohol while taking Imaverol?

According to the official product information, no interactions are known between Imaverol and other substances, including alcohol. Regulatory documents do not designate any specific timing separation rules or restrictions regarding alcohol use.

Q: What is the average reported duration of treatment with Imaverol?

The official treatment schedule defines the duration by the number of applications required. The standard course involves a total of 4 applications, with an interval of 3 days between each one.

Q: How is the action of Imaverol different from other antifungal agents?

Imaverol's active ingredient, Enilconazole, is classified as a synthetic broad-spectrum Azole antifungal. It is described as a selective inhibitor of the P450-dependent C14alpha-demethylase enzyme, which plays a role in fungal sterol synthesis. This specific action disrupts the production of ergosterol, which is essential for the fungal cell membrane's structure.

Q: Why does the packaging for Imaverol have specific warnings about contact with eyes?

The chemical substance in the product is chemically classified as causing serious eye irritation. Official documentation states that protective gear should be worn by the administrator and specifies that in the event of accidental exposure, the eye should be flushed thoroughly with running water.

Q: What is the difference between the active and inactive ingredients in Imaverol?

The active ingredient is Enilconazole, which provides the therapeutic effect against fungal infections. The inactive ingredients, or excipients, are necessary components that ensure the product’s stability, proper form, and safe delivery, and they are fully listed in the regulatory composition document.

Q: What age group is Imaverol generally recommended for?

The official product profile generally permits the use of the medicine in young animals such as calves, foals, and puppies. This is based on the fact that there are no explicit age-based restrictions or contraindications listed in the regulatory documents.

Q: Why is Imaverol sometimes called by a different name?

Official documents define the product by its trade name (Imaverol) and its active substance (Enilconazole). It is common for medicines to be sold under different trade names in various regions, but the core active substance remains the same as defined in the regulatory composition.

Q: Where can I find the official prescribing information for Imaverol?

The comprehensive official prescribing information is contained in the Summary of Product Characteristics (SmPC). This document is typically published by and available on the websites of the relevant government drug regulatory authorities, such as the EMA or VMD.

Q: What should I look for in the official documents about safety warnings?

Safety details are found in the official documents under the sections titled 'Adverse Reactions (frequency and seriousness)' and 'Special precautions for use.' These sections outline known side effects, safety limitations, and mandatory protective measures for the administrator.

Q: Are there specific research studies that support the use of Imaverol?

The regulatory evidence file supporting the medicine's authorization includes data from both controlled clinical trials and field studies. These studies monitored the evolution of skin signs and fungal culture status across the authorized animal species.

Q: Is there a generic version of Imaverol available?

Imaverol is the authorized trade name for a specific concentration of the active substance Enilconazole. Other veterinary products containing Enilconazole as the active substance may be authorized and marketed under different trade names internationally.

Q: Is Imaverol known to cause any long-term effects?

The available regulatory data includes limited information on long-term outcomes following treatment completion. Official research reports state that the full implications are not fully established across all target species in the research record.

Q: Can Imaverol be used if I have allergies to certain medications?

The product is contraindicated, or advised against, only in cases of documented hypersensitivity (allergy) to the active substance (Enilconazole) or any of the inactive ingredients (excipients) listed in the regulatory documents.

Q: What are the official guidelines on stopping the use of Imaverol?

The official treatment regimen describes a course of 3 to 4 applications repeated at 3-day intervals. The course is typically complete after the final scheduled application. The course may be extended in severe cases, as described in the label, under professional guidance.

Q: Is it common for Imaverol to cause temporary skin discoloration?

Official regulatory documents describing reported adverse reactions do not list temporary skin discoloration as a reported side effect or local reaction.

Q: Is Imaverol sold under any other brand names internationally?

Imaverol is a registered trade name. The active ingredient, Enilconazole, is authorized and marketed by the original manufacturer or licensees under different trade names in various international regions.

Q: Does Imaverol have a black box warning in the US (FDA documents)?

The product's primary regulatory authorizations are found outside the United States. The FDA has not issued a Black Box Warning for Imaverol because the product is not currently authorized or available in the United States.

Q: Why do official sources sometimes use complex technical terms to describe Imaverol?

Official regulatory documents, such as the Summary of Product Characteristics, are written primarily for prescribing veterinary professionals and regulatory authorities. This audience requires the use of precise scientific and technical terminology to describe the drug's composition, mechanism, and clinical data without ambiguity.

Q: Does Imaverol cause fatigue or drowsiness?

Official documents list Lethargy as a rare adverse reaction observed in animals. This systemic effect has been noted only following accidental ingestion of the product.

Q: Why is Imaverol sometimes mentioned alongside treatments for skin issues?

The official regulatory indication for Imaverol is the treatment of dermatomycoses (fungal skin infections/ringworm) in the authorized animal species. This aligns its purpose directly with the treatment of skin issues.

Imaverol Concentrate for Cutaneous Emulsion must be stored and handled according to specific conditions defined by regulatory documents to maintain stability.

Storage Requirements

• Temperature and Protection: The product must be stored at a temperature not exceeding 25°C and must be kept in the outer carton to protect it from light.
• Shelf Life: The unopened concentrate is stable for 3 years. After the immediate packaging is first opened, the shelf life of the concentrate is 3 months. The stability period for the diluted emulsion (1:50) is 6 weeks.
• Child Safety: Imaverol must be kept out of the sight and reach of children.

Disposal Instructions

All unused product or waste materials must be discarded in accordance with guidance from the local waste regulation authority. It is explicitly stated that the product must not be allowed to contaminate streams or water supplies.